verified SJR 1,614 · Q1 • database Scopus / SJR & Web of Science indexed

United Kingdom · SAGE Publications Ltd

workspace_premium Q1 — Pharmacology visibility_off Single blind Peer Review lock_open Open Access

Therapeutic Advances in Neurological Disorders

Therapeutic Advances in Neurological Disorders is a journal indexed in SJR in Pharmacology and Neurology (clinical) with an H index of 75. It is an CC BY-NC Journal with a Single blind Peer Review review system, and It has a price of 1800 €. The scope of the journal is focused on neurological disorders, neurology. It has an SJR impact factor of 1,614 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,614.

ISSN: 1756-2856

Publisher: SAGE Publications Ltd

Category: Pharmacology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Author guidelines

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

1,614 Q1

H-index 75

Acceptance rate pie_chart

29% Selective

Source Acceptance_Rate

Time to publication hourglass_top

15 weeks

Field Average_time_publication_weeks

Publication cost (APC) payments

1.800 € Open Access

Non-OA path NPD

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,614

H-index

Docs (year)

101

Docs 3y

274

Total refs

4379

Cites 3y

1276

Citable 3y

258

Cites/Doc 2y

3.97

Ref/Doc

43.36

Immediate OA

1800 €

Embargoed OA

NPD

Non OA / Submission

- €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Biomechanical analysis of spasticity treatment in patients with multiple sclerosis

Ventricular tachycardia during basilar-type migraine attack

Correlation of hyperglycemia with mortality after acute ischemic stroke

Clinical experience with repository corticotropin injection in patients with multiple sclerosis experiencing mood changes with intravenous methylprednisolone: a case series

Clinical diagnosis of bilateral vestibular loss: three simple bedside tests

Children with multiple sclerosis should not become therapeutic hostages

Chemotherapeutics in the treatment of multiple sclerosis

Challenges and controversies in the medical management of primary and antithrombotic-related intracerebral hemorrhage

Capsaicinoids in the treatment of neuropathic pain: a review

Brivaracetam: a novel antiepileptic drug for focal-onset seizures

Brivaracetam as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy: the current evidence base

Botulinum toxin in the management of blepharospasm: current evidence and recent developments

SHOW MORE ARTICLES

Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experience

A one-year prospective, randomized, placebo-controlled, quadruple-blinded, phase II safety pilot trial of combination therapy with interferon beta-1a and mycophenolate mofetil in early relapsing - remitting multiple sclerosis (TIME MS)

Biological outcome measurements for behavioral interventions in multiple sclerosis

Best practice in the use of natalizumab in multiple sclerosis

Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy

Antiviral agents in Alzheimer's disease: hope for the future?

Anti-aquaporin-4 antibodies in Devic's neuromyelitis optica: therapeutic implications

An update on the evidence base for peginterferon beta1a in the treatment of relapsing-remitting multiple sclerosis

Advances in the diagnosis, immunopathogenesis and therapies of IgM-anti-MAG antibody-mediated neuropathies

A review of the efficacy and safety of eslicarbazepine acetate in the management of partial-onset seizures

A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis

A preclinical trial of sialic acid metabolites on distal myopathy with rimmed vacuoles/ hereditary inclusion body myopathy, a sugar-deficient myopathy: a review

FAQs

Therapeutic Advances in Neurological Disorders has an SJR of 1,614 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 1800 EUR.

The acceptance rate recorded for Therapeutic Advances in Neurological Disorders is 29%.

Therapeutic Advances in Neurological Disorders

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Therapeutic Advances in Neurological Disorders?

What is the APC / publication cost?

What is the acceptance rate?